AACR 2014: NCI/NIH-Sponsored Session: Large-Scale Genomics Data for the Research Community through the NCI Center for Cancer Genomics

Tuesday, April 8, 2014, 10:30 am - 12:30 pm
Room 28A-C, San Diego Convention Center, San Diego, Calif.

The NCI’s Center for Cancer Genomics (CCG), which includes the Office of Cancer Genomics and The Cancer Genome Atlas Program Office, provides the research community access to large-scale molecular characterization data, which is largely sequence-based. CCG programs aim to improve patient outcome through identification of valid molecular targets and associated molecular markers (prognostic or diagnostic), in and across diseases investigated, which should ultimately lead to the rapid development of novel, more effective therapies. Current CCG initiatives include the Cancer Genome Characterization Initiative (CGCI), Therapeutically Applicable Research to Generate Effective Treatments (TARGET), and The Cancer Genome Atlas (TCGA). The project web pages include details of the studies, as well as information on how to access the data generated. 

TARGET and TCGA are comprehensive genome-wide molecular characterization initiatives to discover the molecular changes that drive the development and progression of certain childhood and adult cancers. The session will report briefly on program missions and goals of the CCG initiatives, discuss published results, as well as outline various ways for the broad research community to access genomics data including next-generation sequencing. TARGET investigators will highlight discoveries and lessons learned from the projects in Acute Lymphoblastic Leukemia (ALL) and Neuroblastoma. TCGA researchers will additionally provide overviews of recent publications: Comprehensive Molecular Characterization of Gastric Adenocarcinoma, which described four subtypes emerging from a “cluster of clusters” analysis, Comprehensive Molecular Characterization of Clear Cell Renal Cell Carcinoma, which found that metabolic shift correlated with tumor stage and severity, Diversity of Lung Adenocarcinoma Revealed by Integrative Molecular Profiling, which uncovered changes that may expand the number of potential molecular targets, and The Somatic Genomic Landscape of Glioblastoma, which analyzed of the genomic data generated from 590 GBM cases.

Session Co-Chairpersons: Jaime M. Guidry Auvil, Ph.D. and Jean-Claude Zenklusen, Ph.D., NCI, Bethesda, Md.

  • TARGET Initiative Overview & Highlights: Jaime M. Guidry Auvil, Ph.D., NCI
    • Neuroblastoma: John M. Maris, M.D., Children’s Hospital of Philadelphia
    • Acute Lymphoblastic Leukemia: Charles G. Mullighan, M.D., Ph.D., St. Jude Children’s Research Hospital
  • Accessing TARGET Genomics Data: Tanja M. Davidsen, Ph.D., NCI
  •  TCGA Initiative Data Overview: Jean-Claude Zenklusen, Ph.D., NCI
    • Gastric Adenocarcinoma: Peter W. Laird, Ph.D., USC Epigenome Center
    • Renal Cell Carcinoma: Chad J. Creighton, Ph.D., Baylor College of Medicine
    • Lung Adenocarcinoma: Matthew L. Meyerson, M.D., Ph.D., Dana-Farber Cancer Institute
    • Glioblastoma: Lynda Chin, M.D., MD Anderson Cancer Center


  • TARGET initiative overview & highlights
    • Jaime Guidry Auvil. National Cancer Institute, Bethesda, Md.
  • Acute lymphoblastic leukemia
    • Charles G. Mullighan. St. Jude Children's Research Hospital, Memphis, Tenn.
  • Neuroblastoma
    • John Maris. Children's Hospital of Philadelphia, Philadelphia, Pa.
  • Accessing TARGET genomics data
    • Tanja M. Davidsen. National Cancer Institute, Bethesda, Md.
  • TCGA initiative data overview
    • Jean C. Zenklusen. National Cancer Inst., Bethesda, Md.
  • Gastric adenocarcinoma
    • Peter W. Laird. USC, Los Angeles, Calif.
  • Renal cell carcinoma
    • Chad J. Creighton. Baylor College of Medicine, Houston, Texas
  • Lung adenocarcinoma
    • Matthew L. Meyerson. Dana-Farber Cancer Inst., Boston, Mass.
  • Glioblastoma
    • Lynda Chin. UT MD Anderson Cancer Ctr., Houston, Texas

For more information, please visit the AACR website.